Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2023 Jun 27:2023:4747989.
doi: 10.1155/2023/4747989. eCollection 2023.

IgE Plasma Cell Leukemia Harboring t(11;14) and 1q Amplification

Affiliations
Case Reports

IgE Plasma Cell Leukemia Harboring t(11;14) and 1q Amplification

Wataru Nakahara et al. Case Rep Hematol. .

Abstract

IgE plasma cell neoplasm is the rarest subtype of plasma cell neoplasms and is known for its poor prognosis and high incidence of t(11;14). However, t(11;14) has been classified as a standard-risk rather than high-risk cytogenetic abnormality in multiple myeloma. We have been unable to explain the discrepancy that the hallmark of IgE plasma cell neoplasm with a poor prognosis is a standard-risk cytogenetic abnormality. Here, we report a case of IgE primary plasma cell leukemia with extramedullary lesions of the liver, stomach, and lymph nodes. Plasma cell infiltration was pathologically confirmed in each organ. Cytogenetic analysis of plasma cells revealed t(11;14) and amplification of 1q21. Chemotherapy, with immunomodulatory imide drugs, proteasome inhibitors, and CD38 antibodies, was unsuccessful. In IgE plasma cell neoplasm, coexistence of other cytogenetic abnormalities with t(11;14) may be important. Investigating the presence of cytogenetic abnormalities coexisting with t(11;14) is not only useful for evaluating prognosis but also important for understanding the pathogenesis of the disease. Recently, venetoclax, an oral BCL2 inhibitor, has demonstrated promising efficacy in plasma cell neoplasm patients harboring t(11;14). Development of an effective venetoclax-based regimen for treating aggressive IgE plasma cell neoplasm with t(11;14) is expected.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflicts of interest.

Figures

Figure 1
Figure 1
(a) Serum immunofixation demonstrating a monoclonal IgE kappa (κ) component, (b) interphase fluorescence in situ hybridization (FISH) with dual fusion probes for immunoglobulin heavy chain (IGH) and cyclin D1 (CCND1) showed a fusion signal corresponding to t(11;14)/IGH-CCND1 fusion (white arrow), and (c) interphase FISH with a probe for cyclin-dependent kinases regulatory subunit 1 (CKS1B), a chromosome 1q marker, showed four copies of CKS1B. ELP: serum protein electrophoresis.
Figure 2
Figure 2
Computed tomography revealed bilateral pleural effusion (a), multiple hypodense liver nodules (b–d), thickening of the stomach wall (b), ascites (b–d), and swelling of multiple lymph nodes (red boxes in (a–d)).
Figure 3
Figure 3
Histopathological examination of biopsy samples from the liver and gastric mucosa. The plasma cells had diffusely infiltrated the liver (a–c) and gastric mucosa (d–f) (hematoxylin-eosin staining, ×400). The plasma cells were positive for CD138 (b and e) and cyclin D1 (c and f) (×200). HE: hematoxylin-eosin staining.

Similar articles

Cited by

References

    1. Pandey S., Kyle R. A. Unusual myelomas: a review of IgD and IgE variants. Oncology . 2013;27(8):798–803. - PubMed
    1. Macro M., Andre I., Comby E., et al. IgE multiple myeloma. Leukemia and Lymphoma . 1999;32(5-6):597–603. doi: 10.3109/10428199909058419. - DOI - PubMed
    1. Avet-Loiseau H., Garand R., Lodé L., Harousseau J. L., Bataille R., Intergroupe Francophone du M. Translocation t(11;14)(q13;q32) is the hallmark of IgM, IgE, and nonsecretory multiple myeloma variants. Blood . 2003;101(4):1570–1571. doi: 10.1182/blood-2002-08-2436. - DOI - PubMed
    1. Fernandez de Larrea C., Kyle R., Rosinol L., et al. Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage. Blood Cancer Journal . 2021;11(12):p. 192. doi: 10.1038/s41408-021-00587-0. - DOI - PMC - PubMed
    1. Kyle R. A., Maldonado J. E., Bayrd E. D. Plasma cell leukemia. Report on 17 cases. Archives of Internal Medicine . 1974;133(5):813–818. doi: 10.1001/archinte.133.5.813. - DOI - PubMed

Publication types